Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors ...
Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback